Retinopathy of Prematurity clinical trials at University of California Health
3 in progress, 1 open to eligible people
Bevacizumab Treatment For Type 1 ROP
open to eligible people ages up to 6 months
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral…
at UC Davis UC Irvine UCLA UCSF
Clinical and Genetic Analysis of ROP
Sorry, not currently recruiting here
Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the…
at UCLA
Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
Sorry, accepting new patients by invitation only
Primary objectives of the study are: - To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). - To evaluate long-term safety outcomes in…
at UCSD UCSF
Last updated: